Microbiome Research Evidence Assurance
Assess supplied microbiome-state evidence as research screening without presenting the result as clinical advice or treatment-outcome prediction.
Who this is for
Microbiome research leads, computational-biology teams and translational research reviewers evaluating bounded dysbiosis evidence.
The problem you already have
A diversity shift can look important without explaining the rest of the microbiome state
Part 38 treats dysbiosis as a multi-signal state rather than a single diversity statistic. For a bounded research review, diversity should remain linked to the supplied metabolite, immune-marker and time context so one metric does not silently become the entire conclusion.
Different microbiome signals can disagree about whether the state is actually changing
A candidate condition may show a favorable shift in one supplied measure while another part of the bounded state remains unfavorable or unstable. The useful evidence layer is therefore the consistency of the submitted state as a whole, not an isolated “improvement” label.
Dysbiosis research evidence is not treatment-outcome prediction
Part 38 explicitly limits its biomedical outputs to computational research proxies requiring experimental and clinical validation. This product therefore supports research classification and candidate comparison only; it does not diagnose disease, recommend treatment or predict a validated clinical outcome.
Real-World Operational Scenario: The Candidate That Improved Diversity but Left the Broader State Unresolved
Scenario: A candidate condition increases a supplied diversity measure, but metabolite or immune-marker evidence does not move in the same direction.
A microbiome research team is comparing two candidate conditions before deciding which one deserves a next-stage experiment. One candidate looks better if the review focuses only on diversity.
WITHOUT this check: The diversity improvement can dominate the comparison and the conflicting parts of the supplied microbiome state may survive only as informal caveats.
WITH this check: Diversity, metabolite, immune-marker and time context remain tied together in one bounded evidence record. A conflicting state remains visibly unresolved, while a coherent state can be carried forward for human scientific review without being promoted into a treatment-response claim.
What BivectorAI Provides
Multi-Signal Dysbiosis Evidence
Reviews the supplied microbiome state across the bounded evidence dimensions instead of treating one diversity or composition signal as decisive by itself.
State-Consistency Review
Preserves whether the submitted diversity, metabolite, immune-marker and time evidence tells a coherent story or remains internally conflicting.
Candidate Comparison on One Standard
Applies the same bounded evidence contract across candidate states so the research team can compare which package is more internally consistent for the agreed question.
Research-Only Human Decision Boundary
Outputs remain computational research evidence for scientific review and cannot become diagnosis, treatment guidance, transplant authority or validated clinical outcome prediction.
Prove the Gate Before Broader Integration
Back-test the assessment against frozen microbiome-state packages with known experimental disposition.
Freeze the allowed state fields, classification labels, conflict rules and acceptance criteria before revealing the historical experimental disposition. Broader integration is justified only if the same contract reproducibly distinguishes coherent from conflicting research states without promoting computational screening into a clinical claim.
What you provide
A bounded microbiome-state evidence package containing only the fields required by the agreed research contract and, where already available in your workflow, summarized diversity, metabolite, immune-marker and time-context evidence. Patient-identifying information and treatment authority are not required.
What BivectorAI actually hands you
Bounded dysbiosis classification
A research classification tied directly to the exact submitted microbiome-state package and agreed question.
State-consistency finding
A separate indication of whether the supplied diversity, metabolite, immune-marker and time evidence is coherent or remains conflicting.
Candidate-comparison evidence
An input-linked record that lets the research team compare bounded states under one consistent review contract.
Research evidence certificate
A reviewable result with explicit limitations, human-owned follow-up and fail-closed handling when the supplied contract cannot support a valid classification.
What we will never ask you for
Microbiome research can sit close to sensitive patient and treatment context. The assessment uses only the bounded microbiome-state evidence needed for the agreed research question, while clinical authority and identifying information stay outside scope.
- Clinical diagnosis authority.
- Treatment or transplant decisions.
- Patient-identifying information.
- A claim of validated clinical outcome prediction.
How it actually runs
Start with a bounded evaluation
Fixed scope / quoted per engagement. Inputs, outputs, evidence boundary and acceptance criteria are agreed before work begins.
We do not open with an annual license. If the bounded microbiome review does not establish that the research evidence is useful for the agreed dysbiosis question, there is no reason to move into a broader commercial commitment.
A microbiome assessment operation is implemented within the broader biomedical research dispatcher. The capability is research-only, not a medical device or clinical advice, and does not constitute validated clinical treatment-outcome prediction.